Statistics for Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC) : An open-label, non-randomized, multicenter, phase IV clinical trial
Total visits
| views | |
|---|---|
| Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC) : An open-label, non-randomized, multicenter, phase IV clinical trial | 0 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| Erlotinib_as_single_agent_first_line_treatment.pdf | 3 |